AG˹ٷ

STOCK TITAN

[Form 4] Mesa Laboratories Inc Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Mesa Laboratories, Inc. (MLAB) � Form 4 insider transaction filed 06/20/2025

CFO John Sakys reported activity dated 06/18/2025 involving the exercise and settlement of restricted stock units (RSUs) and related tax withholding.

  • RSU exercise (Code M): 2,840 common shares were issued upon vesting of previously granted RSUs. Each RSU converts 1-for-1 into common stock.
  • Tax withholding (Code F): 1,243 of the newly issued shares were automatically withheld at a reference price of $92.99 to satisfy tax obligations.

After the transactions, Sakys� direct beneficial ownership changed from 12,865 shares to 14,462 shares, a net increase of 1,597 shares (�12.4%).

The RSU award vests in three equal annual installments beginning 06/18/2025, providing future potential share deliveries on the next two anniversary dates.

No derivative positions remain other than 5,511 unvested RSUs outstanding.

Because the share acquisition arose from planned equity compensation rather than open-market buying, the filing signals routine ownership growth rather than an active market purchase, though the net increase modestly aligns the CFO’s incentives with shareholders.

Mesa Laboratories, Inc. (MLAB) � Comunicazione Form 4 insider del 20/06/2025

Il CFO John Sakys ha segnalato un’attività datata 18/06/2025 riguardante l’esercizio e la liquidazione di unità azionarie vincolate (RSU) e la relativa ritenuta fiscale.

  • Esercizio RSU (Codice M): sono state emesse 2.840 azioni ordinarie in seguito alla maturazione delle RSU precedentemente assegnate. Ogni RSU si converte 1 a 1 in azioni ordinarie.
  • Ritenuta fiscale (Codice F): 1.243 delle nuove azioni emesse sono state automaticamente trattenute a un prezzo di riferimento di 92,99$ per soddisfare gli obblighi fiscali.

Dopo queste operazioni, la proprietà diretta di Sakys è passata da 12.865 azioni a 14.462 azioni, con un incremento netto di 1.597 azioni (circa il 12,4%).

Il premio RSU matura in tre rate annuali uguali a partire dal 18/06/2025, offrendo potenziali consegne di azioni future nelle prossime due date di anniversario.

Non risultano altre posizioni derivanti oltre a 5.511 RSU non ancora maturate.

Poiché l’acquisizione delle azioni deriva da un piano di compensazione azionaria programmato e non da acquisti sul mercato aperto, la comunicazione indica una crescita ordinaria della proprietà piuttosto che un acquisto attivo, anche se l’aumento netto allinea modestamente gli interessi del CFO con quelli degli azionisti.

Mesa Laboratories, Inc. (MLAB) � Presentación del Formulario 4 de operaciones internas el 20/06/2025

El CFO John Sakys reportó una actividad fechada el 18/06/2025 relacionada con el ejercicio y liquidación de unidades de acciones restringidas (RSU) y la retención fiscal correspondiente.

  • Ejercicio de RSU (Código M): se emitieron 2,840 acciones ordinarias al consolidarse las RSU previamente otorgadas. Cada RSU se convierte 1 a 1 en acciones ordinarias.
  • Retención fiscal (Código F): 1,243 de las nuevas acciones emitidas fueron retenidas automáticamente a un precio de referencia de $92.99 para cubrir obligaciones fiscales.

Tras estas transacciones, la propiedad directa de Sakys cambió de 12,865 acciones a 14,462 acciones, un aumento neto de 1,597 acciones (aproximadamente 12.4%).

El premio de RSU se consolida en tres cuotas anuales iguales a partir del 18/06/2025, lo que brinda entregas potenciales de acciones en los próximos dos aniversarios.

No quedan posiciones derivadas además de 5,511 RSU no consolidadas.

Dado que la adquisición de acciones proviene de una compensación accionaria planificada y no de compras en el mercado abierto, la presentación indica un crecimiento rutinario en la propiedad más que una compra activa en el mercado, aunque el aumento neto alinea modestamente los incentivos del CFO con los accionistas.

Mesa Laboratories, Inc. (MLAB) � 2025� 6� 20� 제출� Form 4 내부� 거래 보고

CFO John Sakys가 2025� 6� 18일자� 제한 주식 단위(RSU) 행사 � 정산� 관� 세금 원천징수 활동� 보고했습니다.

  • RSU 행사(코드 M): 이전� 부여된 RSU가 성숙하여 2,840주의 보통주가 발행되었습니�. � RSU� 1대 1� 보통주로 전환됩니�.
  • 세금 원천징수(코드 F): 세금 납부� 위해 발행� 신규 주식 � 1,243주가 기준 가� $92.99� 자동으로 원천징수되었습니�.

� 거래 � Sakys� 직접 보유 주식 수는 12,865주에� 14,462�� 순증가 1,597�(� 12.4%)� 기록했습니다.

RSU 보상은 2025� 6� 18일부� 시작하여 3년에 걸쳐 동일� � 번의 분할� 성숙하며, 다음 � 기념일에 추가 주식 지� 가능성� 있습니다.

5,511주의 미성� RSU 외에 다른 파생 포지션은 없습니다.

이번 주식 취득은 공개 시장에서� 매수가 아닌 계획� 주식 보상에서 발생했으므�, 이번 보고� 적극적인 시장 매수보다� 일상적인 소유� 증가� 나타내며, 순증가� CFO� 인센티브� 주주들과 어느 정도 일치시키� 효과가 있습니다.

Mesa Laboratories, Inc. (MLAB) � Déclaration Formulaire 4 d’initié déposée le 20/06/2025

Le CFO John Sakys a rapporté une opération datée du 18/06/2025 concernant l’exercice et le règlement d’unités d’actions restreintes (RSU) ainsi que la retenue fiscale associée.

  • Exercice de RSU (Code M) : 2 840 actions ordinaires ont été émises suite à la levée des restrictions des RSU précédemment attribuées. Chaque RSU se convertit en une action ordinaire à 1 pour 1.
  • Retenue fiscale (Code F) : 1 243 des actions nouvellement émises ont été automatiquement retenues à un prix de référence de 92,99 $ pour satisfaire aux obligations fiscales.

Après ces opérations, la propriété directe de Sakys est passée de 12 865 actions à 14 462 actions, soit une augmentation nette de 1 597 actions (environ 12,4 %).

La remise des RSU s’effectue en trois versements annuels égaux à partir du 18/06/2025, offrant des livraisons potentielles d’actions lors des deux prochains anniversaires.

Aucune position dérivée ne subsiste, hormis 5 511 RSU non acquises.

Étant donné que l’acquisition des actions résulte d’une rémunération en actions planifiée et non d’achats sur le marché libre, la déclaration indique une croissance régulière de la participation plutôt qu’un achat actif, bien que cette augmentation nette aligne modestement les intérêts du CFO avec ceux des actionnaires.

Mesa Laboratories, Inc. (MLAB) � Form 4 Insider-Transaktion eingereicht am 20.06.2025

CFO John Sakys meldete eine Aktivität vom 18.06.2025 bezüglich der Ausübung und Abwicklung von Restricted Stock Units (RSUs) sowie der dazugehörigen Steuerabzüge.

  • RSU-Ausübung (Code M): 2.840 Stammaktien wurden bei der Vesting der zuvor gewährten RSUs ausgegeben. Jede RSU wandelt sich 1:1 in Stammaktien um.
  • Steuerabzug (Code F): 1.243 der neu ausgegebenen Aktien wurden automatisch zu einem Referenzpreis von 92,99 $ einbehalten, um Steuerverpflichtungen zu erfüllen.

Nach den Transaktionen änderte sich Sakys� direkte wirtschaftliche Beteiligung von 12.865 Aktien auf 14.462 Aktien, eine Nettoerhöhung um 1.597 Aktien (ca. 12,4 %).

Die RSU-Zuteilung vestet in drei gleichen jährlichen Raten beginnend am 18.06.2025, was zukünftige potenzielle Aktienlieferungen an den nächsten beiden Jahrestagen vorsieht.

Es bestehen keine weiteren derivativen Positionen außer 5.511 nicht vesteten RSUs.

Da der Aktienerwerb aus einer geplanten Aktienvergütung und nicht aus offenen Markttransaktionen resultiert, signalisiert die Meldung ein routinemäßiges Wachstum des Eigentums und keinen aktiven Marktkauf, wobei die Nettoerhöhung die Anreize des CFO in gewissem Maße mit den Aktionären in Einklang bringt.

Positive
  • Net increase of 1,597 shares in CFO ownership, signalling continued alignment with shareholders
  • Three-year RSU vesting schedule encourages long-term performance focus
Negative
  • None.

Insights

TL;DR CFO gained 1,597 net shares via RSU vesting; routine, mildly positive alignment, limited trading signal.

The filing shows conversion of long-term compensation rather than discretionary buying. Sakys� ownership rose 12%, now 14,462 shares, indicating continuing equity stake. No open-market sale occurred; the only disposition was automatic tax withholding at $92.99. Such routine Form 4s generally have low market impact, yet incremental insider ownership can be viewed as a modestly constructive governance sign. There is no information on company performance, so the event should not materially affect valuation or near-term trading dynamics.

TL;DR Standard equity-comp vesting; strengthens pay-for-performance linkage, no red flags.

The three-year RSU schedule aligns management with long-term shareholder value. Automatic share withholding (Code F) follows best-practice tax compliance. No accelerated vesting, hedging, or 10b5-1 plan usage was disclosed, suggesting adherence to internal trading policies. Overall governance implications are neutral-to-positive, with minimal risk indicators.

Mesa Laboratories, Inc. (MLAB) � Comunicazione Form 4 insider del 20/06/2025

Il CFO John Sakys ha segnalato un’attività datata 18/06/2025 riguardante l’esercizio e la liquidazione di unità azionarie vincolate (RSU) e la relativa ritenuta fiscale.

  • Esercizio RSU (Codice M): sono state emesse 2.840 azioni ordinarie in seguito alla maturazione delle RSU precedentemente assegnate. Ogni RSU si converte 1 a 1 in azioni ordinarie.
  • Ritenuta fiscale (Codice F): 1.243 delle nuove azioni emesse sono state automaticamente trattenute a un prezzo di riferimento di 92,99$ per soddisfare gli obblighi fiscali.

Dopo queste operazioni, la proprietà diretta di Sakys è passata da 12.865 azioni a 14.462 azioni, con un incremento netto di 1.597 azioni (circa il 12,4%).

Il premio RSU matura in tre rate annuali uguali a partire dal 18/06/2025, offrendo potenziali consegne di azioni future nelle prossime due date di anniversario.

Non risultano altre posizioni derivanti oltre a 5.511 RSU non ancora maturate.

Poiché l’acquisizione delle azioni deriva da un piano di compensazione azionaria programmato e non da acquisti sul mercato aperto, la comunicazione indica una crescita ordinaria della proprietà piuttosto che un acquisto attivo, anche se l’aumento netto allinea modestamente gli interessi del CFO con quelli degli azionisti.

Mesa Laboratories, Inc. (MLAB) � Presentación del Formulario 4 de operaciones internas el 20/06/2025

El CFO John Sakys reportó una actividad fechada el 18/06/2025 relacionada con el ejercicio y liquidación de unidades de acciones restringidas (RSU) y la retención fiscal correspondiente.

  • Ejercicio de RSU (Código M): se emitieron 2,840 acciones ordinarias al consolidarse las RSU previamente otorgadas. Cada RSU se convierte 1 a 1 en acciones ordinarias.
  • Retención fiscal (Código F): 1,243 de las nuevas acciones emitidas fueron retenidas automáticamente a un precio de referencia de $92.99 para cubrir obligaciones fiscales.

Tras estas transacciones, la propiedad directa de Sakys cambió de 12,865 acciones a 14,462 acciones, un aumento neto de 1,597 acciones (aproximadamente 12.4%).

El premio de RSU se consolida en tres cuotas anuales iguales a partir del 18/06/2025, lo que brinda entregas potenciales de acciones en los próximos dos aniversarios.

No quedan posiciones derivadas además de 5,511 RSU no consolidadas.

Dado que la adquisición de acciones proviene de una compensación accionaria planificada y no de compras en el mercado abierto, la presentación indica un crecimiento rutinario en la propiedad más que una compra activa en el mercado, aunque el aumento neto alinea modestamente los incentivos del CFO con los accionistas.

Mesa Laboratories, Inc. (MLAB) � 2025� 6� 20� 제출� Form 4 내부� 거래 보고

CFO John Sakys가 2025� 6� 18일자� 제한 주식 단위(RSU) 행사 � 정산� 관� 세금 원천징수 활동� 보고했습니다.

  • RSU 행사(코드 M): 이전� 부여된 RSU가 성숙하여 2,840주의 보통주가 발행되었습니�. � RSU� 1대 1� 보통주로 전환됩니�.
  • 세금 원천징수(코드 F): 세금 납부� 위해 발행� 신규 주식 � 1,243주가 기준 가� $92.99� 자동으로 원천징수되었습니�.

� 거래 � Sakys� 직접 보유 주식 수는 12,865주에� 14,462�� 순증가 1,597�(� 12.4%)� 기록했습니다.

RSU 보상은 2025� 6� 18일부� 시작하여 3년에 걸쳐 동일� � 번의 분할� 성숙하며, 다음 � 기념일에 추가 주식 지� 가능성� 있습니다.

5,511주의 미성� RSU 외에 다른 파생 포지션은 없습니다.

이번 주식 취득은 공개 시장에서� 매수가 아닌 계획� 주식 보상에서 발생했으므�, 이번 보고� 적극적인 시장 매수보다� 일상적인 소유� 증가� 나타내며, 순증가� CFO� 인센티브� 주주들과 어느 정도 일치시키� 효과가 있습니다.

Mesa Laboratories, Inc. (MLAB) � Déclaration Formulaire 4 d’initié déposée le 20/06/2025

Le CFO John Sakys a rapporté une opération datée du 18/06/2025 concernant l’exercice et le règlement d’unités d’actions restreintes (RSU) ainsi que la retenue fiscale associée.

  • Exercice de RSU (Code M) : 2 840 actions ordinaires ont été émises suite à la levée des restrictions des RSU précédemment attribuées. Chaque RSU se convertit en une action ordinaire à 1 pour 1.
  • Retenue fiscale (Code F) : 1 243 des actions nouvellement émises ont été automatiquement retenues à un prix de référence de 92,99 $ pour satisfaire aux obligations fiscales.

Après ces opérations, la propriété directe de Sakys est passée de 12 865 actions à 14 462 actions, soit une augmentation nette de 1 597 actions (environ 12,4 %).

La remise des RSU s’effectue en trois versements annuels égaux à partir du 18/06/2025, offrant des livraisons potentielles d’actions lors des deux prochains anniversaires.

Aucune position dérivée ne subsiste, hormis 5 511 RSU non acquises.

Étant donné que l’acquisition des actions résulte d’une rémunération en actions planifiée et non d’achats sur le marché libre, la déclaration indique une croissance régulière de la participation plutôt qu’un achat actif, bien que cette augmentation nette aligne modestement les intérêts du CFO avec ceux des actionnaires.

Mesa Laboratories, Inc. (MLAB) � Form 4 Insider-Transaktion eingereicht am 20.06.2025

CFO John Sakys meldete eine Aktivität vom 18.06.2025 bezüglich der Ausübung und Abwicklung von Restricted Stock Units (RSUs) sowie der dazugehörigen Steuerabzüge.

  • RSU-Ausübung (Code M): 2.840 Stammaktien wurden bei der Vesting der zuvor gewährten RSUs ausgegeben. Jede RSU wandelt sich 1:1 in Stammaktien um.
  • Steuerabzug (Code F): 1.243 der neu ausgegebenen Aktien wurden automatisch zu einem Referenzpreis von 92,99 $ einbehalten, um Steuerverpflichtungen zu erfüllen.

Nach den Transaktionen änderte sich Sakys� direkte wirtschaftliche Beteiligung von 12.865 Aktien auf 14.462 Aktien, eine Nettoerhöhung um 1.597 Aktien (ca. 12,4 %).

Die RSU-Zuteilung vestet in drei gleichen jährlichen Raten beginnend am 18.06.2025, was zukünftige potenzielle Aktienlieferungen an den nächsten beiden Jahrestagen vorsieht.

Es bestehen keine weiteren derivativen Positionen außer 5.511 nicht vesteten RSUs.

Da der Aktienerwerb aus einer geplanten Aktienvergütung und nicht aus offenen Markttransaktionen resultiert, signalisiert die Meldung ein routinemäßiges Wachstum des Eigentums und keinen aktiven Marktkauf, wobei die Nettoerhöhung die Anreize des CFO in gewissem Maße mit den Aktionären in Einklang bringt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sakys John

(Last) (First) (Middle)
MESA LABORATORIES, INC.
12100 W. 6TH AVENUE

(Street)
LAKEWOOD CO 80228

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MESA LABORATORIES INC /CO/ [ MLAB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CFO
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/18/2025 M 2,840 A $92.99 15,705 D
Common Stock 06/18/2025 F 1,243 D $92.99 14,462 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units - 7 (1) 06/18/2025 M 2,840 (2) (3) Common Stock 2,840 $0 5,511 D
Explanation of Responses:
1. Each RSU represents a contingent right to receive one share of the Issuer's common stock
2. RSUs that vest 1/3 on June 18, 2025 and each of the next two anniversary dates
3. Not Applicable
John Sakys 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MLAB's Form 4 dated 06/20/2025 disclose?

CFO John Sakys exercised 2,840 RSUs and withheld 1,243 shares for taxes, raising direct ownership to 14,462 shares.

How many Mesa Laboratories shares does the CFO now own?

Following the reported transactions, John Sakys holds 14,462 common shares directly.

Were any shares sold in the open market by the CFO?

No open-market sales occurred; the only disposition was tax withholding (Code F) at $92.99 per share.

What is the vesting schedule of the reported RSUs?

The RSUs vest in three equal tranches: 1/3 on 06/18/2025 and on each of the next two anniversary dates.

Does the filing indicate use of a Rule 10b5-1 trading plan?

The form does not check the Rule 10b5-1(c) box, so no such plan is associated with these transactions.
Mesa Laboratories

NASDAQ:MLAB

MLAB Rankings

MLAB Latest News

MLAB Latest SEC Filings

MLAB Stock Data

525.69M
5.19M
5.75%
95.91%
3.66%
Scientific & Technical Instruments
Industrial Instruments for Measurement, Display, and Control
United States
LAKEWOOD